ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,735.33
0.01%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Verve Therapeutics Inc (VERV)

  7. Verve Therapeutics Inc (VERV) News

Verve Therapeutics (VERV)

Verve Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VERV
DateTimeSourceHeadlineSymbolCompany
31/05/202421:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
31/05/202412:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
31/05/202412:00GlobeNewswire Inc.Verve Therapeutics Announces Leadership UpdateNASDAQ:VERVVerve Therapeutics Inc
30/05/202421:01GlobeNewswire Inc.Verve Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:VERVVerve Therapeutics Inc
08/05/202412:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VERVVerve Therapeutics Inc
08/05/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
07/05/202412:00GlobeNewswire Inc.Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102NASDAQ:VERVVerve Therapeutics Inc
03/05/202421:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
02/04/202412:00GlobeNewswire Inc.Verve Therapeutics Announces Updates on its PCSK9 ProgramNASDAQ:VERVVerve Therapeutics Inc
28/03/202420:51GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
01/03/202421:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
27/02/202413:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VERVVerve Therapeutics Inc
27/02/202413:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VERVVerve Therapeutics Inc
27/02/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
27/02/202412:30GlobeNewswire Inc.Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
16/02/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
16/02/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
16/02/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
01/02/202411:30GlobeNewswire Inc.Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:VERVVerve Therapeutics Inc
02/01/202411:30GlobeNewswire Inc.Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VERVVerve Therapeutics Inc
01/12/202321:00GlobeNewswire Inc.Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
29/11/202321:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
29/11/202321:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERVVerve Therapeutics Inc
29/11/202311:47Dow Jones NewsVerve Therapeutics Shares Tumble Premarket After Stock SalesNASDAQ:VERVVerve Therapeutics Inc
29/11/202303:37GlobeNewswire Inc.Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
28/11/202321:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERVVerve Therapeutics Inc
28/11/202321:01GlobeNewswire Inc.Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
13/11/202311:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
12/11/202320:30GlobeNewswire Inc.Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:VERVVerve Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VERV

Your Recent History

LSE
0KH0
Pennantpark Floating Rat...
BIT
UC564V
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved